GO:0045661 | regulation of myoblast differentiation | 50.0% (1/2) | 10.55 | 0.000665 | 0.01025 |
GO:0060298 | positive regulation of sarcomere organization | 50.0% (1/2) | 10.55 | 0.000665 | 0.01025 |
GO:2001014 | regulation of skeletal muscle cell differentiation | 50.0% (1/2) | 10.55 | 0.000665 | 0.01025 |
GO:0010831 | positive regulation of myotube differentiation | 50.0% (1/2) | 10.8 | 0.000563 | 0.011342 |
GO:1905868 | regulation of 3'-UTR-mediated mRNA stabilization | 50.0% (1/2) | 10.8 | 0.000563 | 0.011342 |
GO:1905870 | positive regulation of 3'-UTR-mediated mRNA stabilization | 50.0% (1/2) | 10.8 | 0.000563 | 0.011342 |
GO:1990715 | mRNA CDS binding | 50.0% (1/2) | 10.8 | 0.000563 | 0.011342 |
GO:0007319 | negative regulation of oskar mRNA translation | 50.0% (1/2) | 10.08 | 0.000921 | 0.011488 |
GO:0046011 | regulation of oskar mRNA translation | 50.0% (1/2) | 10.08 | 0.000921 | 0.011488 |
GO:0060297 | regulation of sarcomere organization | 50.0% (1/2) | 10.08 | 0.000921 | 0.011488 |
GO:0060485 | mesenchyme development | 50.0% (1/2) | 10.67 | 0.000614 | 0.011489 |
GO:0001947 | heart looping | 50.0% (1/2) | 9.13 | 0.00179 | 0.011725 |
GO:0003143 | embryonic heart tube morphogenesis | 50.0% (1/2) | 9.13 | 0.00179 | 0.011725 |
GO:0035282 | segmentation | 50.0% (1/2) | 9.13 | 0.00179 | 0.011725 |
GO:0031571 | mitotic G1 DNA damage checkpoint signaling | 50.0% (1/2) | 9.08 | 0.001841 | 0.011766 |
GO:0001756 | somitogenesis | 50.0% (1/2) | 9.8 | 0.001125 | 0.011794 |
GO:0097157 | pre-mRNA intronic binding | 50.0% (1/2) | 9.8 | 0.001125 | 0.011794 |
GO:0044819 | mitotic G1/S transition checkpoint signaling | 50.0% (1/2) | 9.04 | 0.001892 | 0.011804 |
GO:0010830 | regulation of myotube differentiation | 50.0% (1/2) | 9.67 | 0.001228 | 0.011913 |
GO:0061158 | 3'-UTR-mediated mRNA destabilization | 50.0% (1/2) | 9.67 | 0.001228 | 0.011913 |
GO:0048702 | embryonic neurocranium morphogenesis | 50.0% (1/2) | 10.25 | 0.000819 | 0.011914 |
GO:0051149 | positive regulation of muscle cell differentiation | 50.0% (1/2) | 9.21 | 0.001688 | 0.011951 |
GO:1990825 | sequence-specific mRNA binding | 50.0% (1/2) | 9.21 | 0.001688 | 0.011951 |
GO:2000738 | positive regulation of stem cell differentiation | 50.0% (1/2) | 9.61 | 0.001279 | 0.011966 |
GO:0048738 | cardiac muscle tissue development | 50.0% (1/2) | 9.93 | 0.001023 | 0.012184 |
GO:0014706 | striated muscle tissue development | 50.0% (1/2) | 9.3 | 0.001586 | 0.012218 |
GO:0051155 | positive regulation of striated muscle cell differentiation | 50.0% (1/2) | 9.3 | 0.001586 | 0.012218 |
GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | 50.0% (1/2) | 9.86 | 0.001074 | 0.012237 |
GO:0110020 | regulation of actomyosin structure organization | 50.0% (1/2) | 9.25 | 0.001637 | 0.012252 |
GO:1903684 | regulation of border follicle cell migration | 50.0% (1/2) | 9.45 | 0.001432 | 0.012508 |
GO:1903688 | positive regulation of border follicle cell migration | 50.0% (1/2) | 9.45 | 0.001432 | 0.012508 |
GO:2000765 | regulation of cytoplasmic translation | 50.0% (1/2) | 9.4 | 0.001483 | 0.012536 |
GO:0030330 | DNA damage response, signal transduction by p53 class mediator | 50.0% (1/2) | 9.35 | 0.001534 | 0.012563 |
GO:0035925 | mRNA 3'-UTR AU-rich region binding | 50.0% (1/2) | 8.9 | 0.002097 | 0.012776 |
GO:0042772 | DNA damage response, signal transduction resulting in transcription | 50.0% (1/2) | 10.93 | 0.000512 | 0.014893 |
GO:0045663 | positive regulation of myoblast differentiation | 50.0% (1/2) | 10.93 | 0.000512 | 0.014893 |
GO:1902809 | regulation of skeletal muscle fiber differentiation | 50.0% (1/2) | 10.93 | 0.000512 | 0.014893 |
GO:2000766 | negative regulation of cytoplasmic translation | 50.0% (1/2) | 10.93 | 0.000512 | 0.014893 |
GO:2001016 | positive regulation of skeletal muscle cell differentiation | 50.0% (1/2) | 10.93 | 0.000512 | 0.014893 |
GO:0009952 | anterior/posterior pattern specification | 50.0% (1/2) | 8.61 | 0.002557 | 0.015224 |
GO:0010634 | positive regulation of epithelial cell migration | 50.0% (1/2) | 8.04 | 0.003783 | 0.015248 |
GO:1902905 | positive regulation of supramolecular fiber organization | 50.0% (1/2) | 8.04 | 0.003783 | 0.015248 |
GO:0048027 | mRNA 5'-UTR binding | 50.0% (1/2) | 8.23 | 0.003323 | 0.015275 |
GO:0060562 | epithelial tube morphogenesis | 50.0% (1/2) | 8.23 | 0.003323 | 0.015275 |
GO:0030371 | translation repressor activity | 50.0% (1/2) | 8.1 | 0.00363 | 0.015338 |
GO:0036002 | pre-mRNA binding | 50.0% (1/2) | 8.1 | 0.00363 | 0.015338 |
GO:0051147 | regulation of muscle cell differentiation | 50.0% (1/2) | 8.28 | 0.003221 | 0.015343 |
GO:1902807 | negative regulation of cell cycle G1/S phase transition | 50.0% (1/2) | 8.28 | 0.003221 | 0.015343 |
GO:0009692 | ethylene metabolic process | 50.0% (1/2) | 8.35 | 0.003068 | 0.015456 |
GO:0009693 | ethylene biosynthetic process | 50.0% (1/2) | 8.35 | 0.003068 | 0.015456 |
GO:0043449 | cellular alkene metabolic process | 50.0% (1/2) | 8.35 | 0.003068 | 0.015456 |
GO:0043450 | alkene biosynthetic process | 50.0% (1/2) | 8.35 | 0.003068 | 0.015456 |
GO:0044773 | mitotic DNA damage checkpoint signaling | 50.0% (1/2) | 8.06 | 0.003732 | 0.015519 |
GO:2000736 | regulation of stem cell differentiation | 50.0% (1/2) | 8.13 | 0.003579 | 0.015626 |
GO:0060537 | muscle tissue development | 50.0% (1/2) | 8.45 | 0.002863 | 0.015629 |
GO:0072331 | signal transduction by p53 class mediator | 50.0% (1/2) | 8.45 | 0.002863 | 0.015629 |
GO:1900673 | olefin metabolic process | 50.0% (1/2) | 8.15 | 0.003527 | 0.015664 |
GO:1900674 | olefin biosynthetic process | 50.0% (1/2) | 8.15 | 0.003527 | 0.015664 |
GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 50.0% (1/2) | 8.3 | 0.00317 | 0.01567 |
GO:0051153 | regulation of striated muscle cell differentiation | 50.0% (1/2) | 8.53 | 0.00271 | 0.015778 |
GO:0043186 | P granule | 50.0% (1/2) | 8.47 | 0.002812 | 0.016017 |
GO:0000381 | regulation of alternative mRNA splicing, via spliceosome | 50.0% (1/2) | 7.93 | 0.004089 | 0.016233 |
GO:0050779 | RNA destabilization | 50.0% (1/2) | 7.81 | 0.004447 | 0.016884 |
GO:0061157 | mRNA destabilization | 50.0% (1/2) | 7.81 | 0.004447 | 0.016884 |
GO:0044774 | mitotic DNA integrity checkpoint signaling | 50.0% (1/2) | 7.85 | 0.004344 | 0.016989 |
GO:0051495 | positive regulation of cytoskeleton organization | 50.0% (1/2) | 7.76 | 0.0046 | 0.017216 |
GO:0000077 | DNA damage checkpoint signaling | 50.0% (1/2) | 7.63 | 0.005059 | 0.018669 |
GO:0010632 | regulation of epithelial cell migration | 50.0% (1/2) | 7.55 | 0.005314 | 0.019338 |
GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 50.0% (1/2) | 7.53 | 0.005416 | 0.01944 |
GO:0042770 | signal transduction in response to DNA damage | 50.0% (1/2) | 7.47 | 0.00562 | 0.0199 |
GO:0003730 | mRNA 3'-UTR binding | 50.0% (1/2) | 7.31 | 0.006284 | 0.021381 |
GO:1902806 | regulation of cell cycle G1/S phase transition | 50.0% (1/2) | 7.32 | 0.006233 | 0.021486 |
GO:0031570 | DNA integrity checkpoint signaling | 50.0% (1/2) | 7.34 | 0.006182 | 0.021595 |
GO:0035239 | tube morphogenesis | 50.0% (1/2) | 7.17 | 0.006947 | 0.023038 |
GO:0061014 | positive regulation of mRNA catabolic process | 50.0% (1/2) | 7.17 | 0.006947 | 0.023038 |
GO:0007093 | mitotic cell cycle checkpoint signaling | 50.0% (1/2) | 7.08 | 0.007355 | 0.024086 |
GO:0002009 | morphogenesis of an epithelium | 50.0% (1/2) | 6.85 | 0.008629 | 0.02791 |
GO:0032956 | regulation of actin cytoskeleton organization | 50.0% (1/2) | 6.71 | 0.009545 | 0.028746 |
GO:2000147 | positive regulation of cell motility | 50.0% (1/2) | 6.71 | 0.009545 | 0.028746 |
GO:0000075 | cell cycle checkpoint signaling | 50.0% (1/2) | 6.77 | 0.009138 | 0.028845 |
GO:1901991 | negative regulation of mitotic cell cycle phase transition | 50.0% (1/2) | 6.77 | 0.009138 | 0.028845 |
GO:0048024 | regulation of mRNA splicing, via spliceosome | 50.0% (1/2) | 6.72 | 0.009494 | 0.029265 |
GO:0030335 | positive regulation of cell migration | 50.0% (1/2) | 6.72 | 0.009444 | 0.029455 |
GO:0043488 | regulation of mRNA stability | 50.0% (1/2) | 6.58 | 0.010411 | 0.029648 |
GO:0032970 | regulation of actin filament-based process | 50.0% (1/2) | 6.59 | 0.01036 | 0.029828 |
GO:0040017 | positive regulation of locomotion | 50.0% (1/2) | 6.55 | 0.010614 | 0.029903 |
GO:0045930 | negative regulation of mitotic cell cycle | 50.0% (1/2) | 6.6 | 0.010309 | 0.030011 |
GO:1902903 | regulation of supramolecular fiber organization | 50.0% (1/2) | 6.6 | 0.010309 | 0.030011 |
GO:0003228 | atrial cardiac muscle tissue development | 50.0% (1/2) | 11.08 | 0.00046 | 0.03016 |
GO:0006978 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | 50.0% (1/2) | 11.08 | 0.00046 | 0.03016 |
GO:0048729 | tissue morphogenesis | 50.0% (1/2) | 6.6 | 0.010258 | 0.030541 |
GO:1903313 | positive regulation of mRNA metabolic process | 50.0% (1/2) | 6.51 | 0.010971 | 0.030578 |
GO:1901988 | negative regulation of cell cycle phase transition | 50.0% (1/2) | 6.47 | 0.011225 | 0.030958 |
GO:0050684 | regulation of mRNA processing | 50.0% (1/2) | 6.38 | 0.011937 | 0.030966 |
GO:0061013 | regulation of mRNA catabolic process | 50.0% (1/2) | 6.38 | 0.011937 | 0.030966 |
GO:0017148 | negative regulation of translation | 50.0% (1/2) | 6.42 | 0.011632 | 0.031098 |
GO:0120255 | olefinic compound biosynthetic process | 50.0% (1/2) | 6.4 | 0.011785 | 0.031188 |
GO:0045727 | positive regulation of translation | 50.0% (1/2) | 6.43 | 0.011581 | 0.031281 |
GO:0034249 | negative regulation of cellular amide metabolic process | 50.0% (1/2) | 6.35 | 0.012192 | 0.031316 |
GO:0043487 | regulation of RNA stability | 50.0% (1/2) | 6.43 | 0.01153 | 0.031468 |
GO:0043484 | regulation of RNA splicing | 50.0% (1/2) | 6.31 | 0.012548 | 0.031917 |
GO:0034250 | positive regulation of cellular amide metabolic process | 50.0% (1/2) | 6.24 | 0.013158 | 0.033147 |
GO:2000113 | negative regulation of cellular macromolecule biosynthetic process | 50.0% (1/2) | 6.11 | 0.014377 | 0.035536 |
GO:0045182 | translation regulator activity | 50.0% (1/2) | 6.12 | 0.014326 | 0.035748 |
GO:0010948 | negative regulation of cell cycle process | 50.0% (1/2) | 6.09 | 0.014631 | 0.035826 |
GO:0030334 | regulation of cell migration | 50.0% (1/2) | 6.03 | 0.015291 | 0.037095 |
GO:2000145 | regulation of cell motility | 50.0% (1/2) | 6.0 | 0.015596 | 0.037487 |
GO:0008285 | negative regulation of cell population proliferation | 50.0% (1/2) | 5.92 | 0.016459 | 0.039202 |
GO:0051493 | regulation of cytoskeleton organization | 50.0% (1/2) | 5.9 | 0.016662 | 0.039328 |
GO:0045786 | negative regulation of cell cycle | 50.0% (1/2) | 5.88 | 0.016966 | 0.039689 |
GO:0048598 | embryonic morphogenesis | 50.0% (1/2) | 5.84 | 0.017372 | 0.039925 |
GO:1901990 | regulation of mitotic cell cycle phase transition | 50.0% (1/2) | 5.85 | 0.017321 | 0.040161 |
GO:0040012 | regulation of locomotion | 50.0% (1/2) | 5.68 | 0.01945 | 0.043556 |
GO:0120254 | olefinic compound metabolic process | 50.0% (1/2) | 5.7 | 0.019146 | 0.04362 |
GO:0010638 | positive regulation of organelle organization | 50.0% (1/2) | 5.68 | 0.019349 | 0.043702 |
GO:0036464 | cytoplasmic ribonucleoprotein granule | 50.0% (1/2) | 5.61 | 0.020312 | 0.045098 |
GO:0035770 | ribonucleoprotein granule | 50.0% (1/2) | 5.59 | 0.020615 | 0.045388 |
GO:1903311 | regulation of mRNA metabolic process | 50.0% (1/2) | 5.58 | 0.020818 | 0.045452 |
GO:0045597 | positive regulation of cell differentiation | 50.0% (1/2) | 5.55 | 0.021274 | 0.046063 |
GO:1901987 | regulation of cell cycle phase transition | 50.0% (1/2) | 5.49 | 0.022134 | 0.047533 |
GO:0031331 | positive regulation of cellular catabolic process | 50.0% (1/2) | 5.46 | 0.022589 | 0.048117 |